Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review
AbstractLangerhans cell histiocytosis (LCH) is a histiocytic neoplasm characterized by a mass of CD1a + CD207 + histiocytes, exhibiting a diverse range of clinical manifestations from a self-healing rash or single bone destruction to multi-organ disease with potentially fatal consequences. The ident...
Saved in:
Main Author: | Qingqing Li (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of BRAF inhibitor (Vemurafenib) in a child with Refractory Langerhans cell histiocytosis
by: Anil Sharma, et al.
Published: (2017) -
Combined treatment with vemurafenib and cobimetinib in Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome: A case Report
by: Hidalgo-Soto Marta, et al.
Published: (2022) -
Gastric Langerhans Cell Histiocytosis: Case Report and Review of the Literature
by: So Jung Lee, et al.
Published: (2015) -
Adult‐onset BRAF V600E‐related multisystem Langerhans cell histiocytosis treated with vemurafenib
by: Lisa Denise A. Encarnacion‐Mangubat, et al.
Published: (2024) -
Isolated Hepatobiliary Involvement in an Infant with Langerhans Cell Histiocytosis: A Case Report with Review of Literature
by: Niva Lakra, et al.
Published: (2023)